Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemiaMonika Brüggemann, Michael Kneba, Silke Lüschen et al.|Blood|2005Cited by 537
Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCRMatthias Ritgen, Peter Dreger, Stephan Stilgenbauer et al.|Blood|2004Cited by 170
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphomaChristiane Pott, Michael Kneba, Carsten Schrader et al.|Blood|2005Cited by 162